The Mounjaro Market in the UK: How It Works and Why It Matters

You've seen Mounjaro offered online for far less than a clinic charges. Here's what that gap usually means.

Imagine you've been quoted £200–£300 a month by a legitimate private clinic, then spotted a social media post offering Mounjaro pens for £80 with same-day delivery. That gap is real, and it reflects something important: the legitimate price includes a prescriber reviewing your medical history, ID verification, weight checks, and ongoing clinical support. The cheaper offer usually omits all of that, and sometimes omits the genuine medicine too.

The UK's private Mounjaro market covers a wide range of providers. Eli Lilly raised its UK list price on 1 September 2025, and the highest dose's list price moved from around £122 to around £330 per four-week pen. Private clinic prices since then typically range roughly £149–£375 per month depending on dose and provider, as widely reported. That span reflects genuine differences in what's included (consultation fees, prescription fees, delivery, aftercare) not all of which are bundled at the advertised headline figure. Our guide to comparing Mounjaro providers sets out what to look for in a breakdown.

A misconception worth setting down gently: many people assume that if a website looks professional and takes payment, it must be regulated. It doesn't follow. Appearance has no bearing on GPhC registration or MHRA compliance. The only reliable check is the GPhC register itself.

The grey market: what it is and what the MHRA found inside it

The term grey market Mounjaro covers pens sold without a prescription through unregulated channels, typically social media sellers, messaging apps, or unregistered websites. These are not a fringe problem. In 2025 the MHRA seized approximately 20 million doses of illegally traded weight-loss medicines worth around £45m, and investigators found the first known UK site manufacturing counterfeit tirzepatide pens, in Northampton. Earlier enforcement had uncovered fake pens containing insulin rather than the labelled medicine, with hospitalisations resulting.

The risks aren't limited to unknown contents. Buying a prescription-only medicine without a clinical assessment means no one has checked whether it interacts with your other medicines, whether your weight-related conditions make it suitable, or whether your dose needs adjusting. For more detail on the Telegram-based and messaging-app routes specifically, our page on grey-market tirzepatide and Telegram covers what's known. The MHRA invites anyone who suspects a seller is trading illegally to report them at the Yellow Card reporting site, the same platform used to report side effects.

Red flags that apply to any Mounjaro offer: pens available without a prescription, prices far below current market range, sellers on social platforms, and any offer of discount codes for a prescription-only medicine. Discount codes for a POM should prompt scepticism rather than excitement.

How the legitimate UK market is structured, NHS versus private

On the NHS, Mounjaro (tirzepatide) is recommended by NICE for weight management under TA1026. Access is phased: from June 2025, adults with a BMI of 40 or above and four or more qualifying conditions (including high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes) became eligible. A second cohort (BMI 35–39.9 with four or more conditions) became eligible from 23 June 2026. From April 2026, GP practices with appropriate contracts may also prescribe. NICE's full recommendation for tirzepatide (TA1026) sets out the eligibility criteria in detail. Waiting times vary by area, and participation is not uniform across GP practices.

For adults who don't meet NHS criteria, or who prefer not to wait, the private route through a GPhC-registered online pharmacy is the legal alternative. The key protection is the prescriber: every supply of Mounjaro requires a valid prescription issued by a clinician who has assessed your suitability. You can confirm any pharmacy's registration at the GPhC register. You can also explore how tirzepatide works as a medicine if you want a grounding in the clinical background before speaking to a prescriber.

The private market also includes treatment options beyond Mounjaro, our weight-loss treatment overview sets out what is currently licensed in the UK for weight management.

What careful patients do before buying anywhere

Three checks cover most of the risk. First, confirm the pharmacy is on the GPhC register before entering any personal or payment details. Second, confirm you will speak to, or be assessed by, a real prescriber, not just complete a short automated questionnaire with no clinical review. Third, be sceptical of any price that seems implausibly low given current list prices, and of any seller who offers to supply without a prior prescription.

If you're already on Mounjaro and want to understand recent changes to the market (including supply shifts and dose availability) the latest Mounjaro update page covers developments as they've happened. For practical questions about using Mounjaro once prescribed, including injection technique, our page on injecting in the thigh is a useful reference.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally, the same day it's submitted. If you'd like to find out whether you're clinically suitable, start your free consultation and we'll give you a straight answer.